AveXis Inc (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.72, for a total transaction of $195,301.60. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at $195,301.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Sukumar Nagendran also recently made the following trade(s):
- On Friday, December 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60.
- On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80.
AveXis Inc (AVXS) traded up $4.75 during trading on Friday, reaching $113.71. 1,140,000 shares of the company’s stock traded hands, compared to its average volume of 663,285. The stock has a market cap of $3,911.01, a PE ratio of -20.38 and a beta of 2.46. AveXis Inc has a 12 month low of $52.18 and a 12 month high of $119.00.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the firm earned ($0.87) EPS. analysts anticipate that AveXis Inc will post -6.23 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in AveXis in the 3rd quarter valued at about $116,000. Ameritas Investment Partners Inc. lifted its position in shares of AveXis by 331.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after purchasing an additional 1,622 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of AveXis in the 3rd quarter worth approximately $200,000. Finally, Deschutes Portfolio Strategy LLC purchased a new stake in shares of AveXis in the 3rd quarter worth approximately $203,000. 92.92% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on AVXS shares. BMO Capital Markets restated an “outperform” rating and issued a $123.00 target price on shares of AveXis in a report on Saturday, September 30th. Citigroup lifted their price target on shares of AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. UBS Group reaffirmed a “buy” rating and set a $122.00 price target (up from $95.00) on shares of AveXis in a research note on Tuesday, October 3rd. Goldman Sachs Group reaffirmed a “buy” rating and set a $130.00 price target on shares of AveXis in a research note on Friday, October 6th. Finally, Jefferies Group lifted their price target on shares of AveXis to $118.00 and gave the stock a “buy” rating in a research note on Thursday, October 12th. Three analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $113.89.
WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/28/sukumar-nagendran-sells-1780-shares-of-avexis-inc-avxs-stock.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.